Vivet Therapeutics is committed to developing an innovative liver-directed gene therapy platform for the treatment of rare and severe inherited metabolic disorders. The company's development strategy is to target the liver with a novel synthetic adeno associated virus to introduce therapeutic genes to hepatocytes.
Vivet's focus is on developing innovative gene therapy technologies and treatments for Wilson disease, Progressive Familiar Intrahepatic Cholestasis, Cirtullinemia and other indications. Vivet's platform leverages new AAV-serotypes, advanced GMP manufacturing processes, disease models and innovative technologies to address current challenges in AAV-based gene therapy.
|Employees (est.) (Jan 2020)||21||(+5%)|
Vivet Therapeutics total Funding
Vivet Therapeutics latest funding size
Time since last funding
|10 months ago|
Vivet Therapeutics investors
|Ysios Capital, Novartis Venture Fund, Roche Venture Fund, Pfizer Venture Investments, HealthCap, Columbus Venture Partners|
Vivet Therapeutics has 152 Twitter Followers. The number of followers has increased 1.3% month over month and increased 4.1% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Vivet Therapeutics founded?
Vivet Therapeutics was founded in 2016.
Who are Vivet Therapeutics key executives?
Vivet Therapeutics's key executives are Gloria Gonzalez-Aseguinolaza, Bernard Bénichou and Susan Coles.
How many employees does Vivet Therapeutics have?
Vivet Therapeutics has 21 employees.
Who are Vivet Therapeutics competitors?
Competitors of Vivet Therapeutics include Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals and Wave Life Sciences.
Where is Vivet Therapeutics headquarters?
Vivet Therapeutics headquarters is located at 80 Boulevard Haussmann, Paris.
Where are Vivet Therapeutics offices?
Vivet Therapeutics has an office in Paris.
How many offices does Vivet Therapeutics have?
Vivet Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies